Komori
Earnings presentation4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Financial Results Briefing for the First Quarter of the Fiscal Year Ending March 2027

In the first quarter of the fiscal year ending March 2027, revenue and operating profit increased across all regions, with strong growth in both net sales and operating profit. Ordinary profit and net income attributable to owners of the parent declined, however, due in part to the year-on-year decrease in dividend income.

Worth reading
82Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
16.8
Year-on-year change in operating profit (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentationFirst quarter of the fiscal year ending March 202714 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales91,624 million yen+11.8%
Operating profit13,663 million yen+16.8%
Ordinary income14,491 million yen-10.1%
Net income10,650 million yen-9.5%
Gross Profit Margin56.3%
Operating profit margin14.9%
Selling, general and administrative expenses37,930 million yen
Results for the three months of the current quarterResults for the three months of the first quarter of the fiscal year ending March 2027, including net sales of ¥91,624 million, operating profit of ¥13,663 million, ordinary profit of ¥14,491 million, and net income attributable to owners of the parent of ¥10,650 million.
Full-year earnings forecast
Net Sales
372,300 million yen
Operating profit
45,000 million yen
Ordinary income
47,400 million yen
Profit attributable to owners of the parent
35,200 million yen
EBITDA
63,700 million yen
Earnings per share
155.78 yen
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Operating profit
31.2 %
Operating income by region
Japan30
Asia34
Americas16.1
Europe47.5
Other7.6
Adjustments21.2
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year-on-year operating profit growth
Revenue up5,403
Cost of sales337
Promotional expenses-652
Advertising spend-1,112
Research and development costs21
Personnel Expenses-914
Other-1,120
Full-year operating profit outlook
Revenue up16,018
Cost of sales185
Promotional expenses-1,440
Advertising spend-2,458
R&D expenses-1,873
Other-6,553
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY158
CNY/JPY exchange rate23
Domestic ConsumptionExpected to remain firm
Inbound DemandUncertainty remains
New initiatives
  • Making Magic Cod, a Serbian cosmetics distributor, a subsidiary
  • Acquisition of the Pain Away topical analgesic brand in Australia
  • Making オーピーバイオファクトリー株式会社 a subsidiary
  • Collaboration with EYS and launch of new products
  • Expanding sales of Rohto eye drops in Eastern Europe
Key KPIsA metric the company considers important as a management benchmark.
  • Hada Labo net sales
    Year on year against the same period last yearLow-teens year-on-year growth
  • Rohto V5 net sales
    Year on year against the same period last year+10.5%
  • Obagi net sales
    Year on year against the same period last year+11.4%
  • Premium eye-drop net sales
    Year on year against the same period last year+13.4%
  • Lip balm net sales
    Year on year against the same period last year+15.3%
  • Sunscreen net sales
    Year on year against the same period last year-4.5%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Hada Labo unit sales and sales value remained firm even after the price increase.
Segment results
Japan
Net Sales
42,864 million yen+5.2%
Operating profit
6,867 million yen+8.8%
Asia
Net Sales
35,604 million yen+19.7%
Operating profit
5,676 million yen+18.8%
Americas
Net Sales
5,465 million yen+8.3%
Operating profit
226 million yen+22.6%
Europe
Net Sales
6,684 million yen+19.9%
Operating profit
664 million yen+392.7%
Other
Net Sales
1,004 million yen+18.9%
Operating profit
37 million yen-48.7%
Medium-term management plan targets
Period CoveredSix-year period from 2025 to 2030
Operating CF
¥3,300 100 million
Capital Expenditure
¥1,000 100 million
Research and development costs
¥900 100 million
DX and IT investment
¥300 100 million
M&A and other activities
¥500 100 million
Shareholder Returns
¥800 100 million
Financial targets
Payout ratioAt least 30%
DOE3.5% or higher
Market Size / Share
Includes Shirojun lotion, the No. 1 drugstore product by unit sales. Market share figures were Not disclosed.
Number of stores and locations
EYS operates more than 187 directly managed stores, primarily in Southeast Asia. The number of store openings and closures during the period was Not disclosed.
Capital expenditures
¥4,855 millions current quarter
Annual Dividend
¥50 per share
Interim Dividend¥25
Year-end dividend¥25
Payout ratio
Expected to be 32.1%. The shareholder return policy calls for a payout ratio of at least 30% and DOE of at least 3.5%.
Acquisition of treasury shares
Up to ¥3 billion
PeriodScheduled for 2026
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFirst quarter of the fiscal year ending March 2027
Net Sales91,624 million yen (YoY +11.8%)
Operating profit13,663 million yen (YoY +16.8%)
Ordinary income14,491 million yen (YoY -10.1%)
Net income10,650 million yen (YoY -9.5%)
Gross Profit Margin56.3%
Operating profit margin14.9%
Selling, general and administrative expenses37,930 million yen
Results for the three months of the current quarterResults for the three months of the first quarter of the fiscal year ending March 2027, including net sales of ¥91,624 million, operating profit of ¥13,663 million, ordinary profit of ¥14,491 million, and net income attributable to owners of the parent of ¥10,650 million.
Full-year earnings forecastNet Sales 372,300 million yen / Operating profit 45,000 million yen / Ordinary income 47,400 million yen / Profit attributable to owners of the parent 35,200 million yen / EBITDA 63,700 million yen / Earnings per share 155.78 yen
Progress against full-year forecastOperating profit 31.2 % / Operating income by region Japan 30 / Asia 34 / Americas 16.1 / Europe 47.5 / Other 7.6 / Adjustments 21.2
Segment resultsJapan Net Sales 42,864 million yen (YoY +5.2%) / Operating profit 6,867 million yen (YoY +8.8%) / Asia Net Sales 35,604 million yen (YoY +19.7%) / Operating profit 5,676 million yen (YoY +18.8%) / Americas Net Sales 5,465 million yen (YoY +8.3%) / Operating profit 226 million yen (YoY +22.6%) / Europe Net Sales 6,684 million yen (YoY +19.9%) / Operating profit 664 million yen (YoY +392.7%) / Other Net Sales 1,004 million yen (YoY +18.9%) / Operating profit 37 million yen (YoY -48.7%)
Breakdown of Factors Affecting the ChangeYear-on-year operating profit growth Revenue up 5,403 / Cost of sales 337 / Promotional expenses -652 / Advertising spend -1,112 / Research and development costs 21 / Personnel Expenses -914 / Other -1,120 / Full-year operating profit outlook Revenue up 16,018 / Cost of sales 185 / Promotional expenses -1,440 / Advertising spend -2,458 / R&D expenses -1,873 / Other -6,553
Key KPIsIndicator name Hada Labo net sales / Value Not disclosed / Year on year against the same period last year Low-teens year-on-year growth, Indicator name Rohto V5 net sales / Value Not disclosed / Year on year against the same period last year +10.5%, Indicator name Obagi net sales / Value Not disclosed / Year on year against the same period last year +11.4%, Indicator name Premium eye-drop net sales / Value Not disclosed / Year on year against the same period last year +13.4%, Indicator name Lip balm net sales / Value Not disclosed / Year on year against the same period last year +15.3%, Indicator name Sunscreen net sales / Value Not disclosed / Year on year against the same period last year -4.5%
Unit price and quantity metricsHada Labo unit sales and sales value remained firm even after the price increase.
Number of stores and locationsEYS operates more than 187 directly managed stores, primarily in Southeast Asia. The number of store openings and closures during the period was Not disclosed.
Assumptions Underlying the Business OutlookUSD/JPY 158 / CNY/JPY exchange rate 23 / Domestic Consumption Expected to remain firm / Inbound Demand Uncertainty remains
Medium-term management plan targetsPeriod Covered Six-year period from 2025 to 2030 / Operating CF ¥3,300 100 million / Capital Expenditure ¥1,000 100 million / Research and development costs ¥900 100 million / DX and IT investment ¥300 100 million / M&A and other activities ¥500 100 million / Shareholder Returns ¥800 100 million
Financial targetsPayout ratio At least 30% / DOE 3.5% or higher
Annual Dividend¥50 per share
Payout ratioExpected to be 32.1%. The shareholder return policy calls for a payout ratio of at least 30% and DOE of at least 3.5%.
Acquisition of treasury sharesAmount Up to ¥3 billion / Period Scheduled for 2026
Capital expenditures¥4,855 millions (current quarter)
Market Size / ShareIncludes Shirojun lotion, the No. 1 drugstore product by unit sales. Market share figures were Not disclosed.
New initiativesMaking Magic Cod, a Serbian cosmetics distributor, a subsidiary, Acquisition of the Pain Away topical analgesic brand in Australia, Making オーピーバイオファクトリー株式会社 a subsidiary, Collaboration with EYS and launch of new products, Expanding sales of Rohto eye drops in Eastern Europe
Items this document does not state (5)
Self-assessment against the planNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Higher sales and an improvement in the cost ratio contributed to the increase in operating profit. Ordinary profit and net income declined, mainly due to the year-on-year decrease in the one-time dividend income recorded in the previous fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing for the First Quarter of the Fiscal Year Ending March 2027 | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori